Weight gain by hyperalimentation elevates C-reactive protein levels but does not affect circulating levels of adiponectin or resistin in healthy subjects

European Journal of Endocrinology

Volumn 163, Issue 6, 2010, Pages 879-885

  Åstrand, Olov ^a   Carlsson, Martin ^b   Nilsson, Ingela ^b   Lindström, Torbjörn ^a   Borga, Magnus ^a   Nystrom, Fredrik H ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b KALMAR COUNTY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; INSULIN; RESISTIN;

ADULT; ARTICLE; CALORIC INTAKE; CONTROLLED STUDY; EXERCISE; FAST FOOD; FEMALE; HUMAN; HUMAN EXPERIMENT; HYPERALIMENTATION; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTERVENTION STUDY; LIFESTYLE; MALE; METABOLIC SYNDROME X; NORMAL HUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; WEIGHT GAIN; BLOOD; HYPERPHAGIA; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADIPONECTIN; ADULT; C-REACTIVE PROTEIN; ENERGY INTAKE; FEMALE; HUMANS; HYPERPHAGIA; INSULIN; INSULIN RESISTANCE; MALE; PROSPECTIVE STUDIES; RESISTIN; WEIGHT GAIN;

EID: 78649833440     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-10-0763     Document Type: Article

References (36)

1. Karastergiou K & Mohamed-Ali V. The autocrine and paracrine roles of adipokines. Molecular and Cellular Endocrinology 2010 318 69-78. (doi:10.1016/j.mce.2009.11.011)
2. Nystrom F, Ekman B, Osterlund M, Lindstrom T, Ohman KP & Arnqvist HJ. Serum leptin concentrations in a normal population and in GH deficiency: negative correlation with testosterone in men and effects of GH treatment. Clinical Endocrinology 1997 47 191-198. (doi:10.1046/j.1365-2265.1997.2281039.x) (Pubitemid 27359899)
3. Ashwin PJ & Dilipbhai PJ. Leptin and the cardiovascular system: a review. Recent Patents on Cardiovascular Drug Discovery 2007 2 100-109. (doi:10.2174/157489007780832533)
4. Li S, Shin HJ, Ding EL & van Dam RM. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. Journal of the American Medical Association 2009 302 179-188. (doi:10.1001/jama.2009.976)
5. Simpson KA & Singh MA. Effects of exercise on adiponectin: a systematic review. Obesity 2008 16 241-256. (doi:10.1038/oby.2007.53)
6. Wang Y, Lam KS, Yau MH & Xu A. Post-translational modifications of adiponectin: mechanisms and functional implications. Biochemical Journal 2008 409 623-633. (doi:10.1042/BJ20071492)
7. Whitehead JP, Richards AA, Hickman IJ, Macdonald GA & Prins JB. Adiponectin - a key adipokine in the metabolic syndrome. Diabetes, Obesity and Metabolism 2006 8 264-280. (doi:10.1111/j.1463-1326.2005.00510.x)
8. Haluzik M & Haluzikova D. The role of resistin in obesity-induced insulin resistance. Current Opinion in Investigational Drugs 2006 7 306-311.
9. Burnett MS, Devaney JM, Adenika RJ, Lindsay R & Howard BV. Cross-sectional associations of resistin, coronary heart disease, and insulin resistance. Journal of Clinical Endocrinology and Metabolism 2006 91 64-68. (doi:10.1210/jc.2005-1653)
10. Azuma K, Katsukawa F, Oguchi S, Murata M, Yamazaki H, Shimada A & Saruta T. Correlation between serum resistin level and adiposity in obese individuals. Obesity Research 2003 11 997-1001. (doi:10.1038/oby.2003.137)
11. Dominguez Coello S, Cabrera de Leon A, Almeida Gonzalez D, Gonzalez Hernandez A, Rodriguez Perez MC, Fernandez Ramos N, Brito Diaz B, Castro Fuentes R & Aguirre Jaime A. Inverse association between serum resistin and insulin resistance in humans. Diabetes Research and Clinical Practice 2008 82 256-261. (doi:10.1016/j.diabres.2008.08.001)
12. Gomez-Ambrosi J & Fruhbeck G. Evidence for the involvement of resistin in inflammation and cardiovascular disease. Current Diabetes Reviews 2005 1 227-234. (doi:10.2174/157339905774574392)
13. Filkova M, Haluzik M, Gay S & Senolt L. The role of resistin as a regulator of inflammation: implications for various human pathologies. Clinical Immunology 2009 133 157-170. (doi:10.1016/j.clim.2009.07.013)
14. Ridker PM, Buring JE, Cook NR & Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003 107 391-397. (doi:10.1161/01.CIR.0000055014.62083.05)
15. Ghanim H, Dhindsa S, Aljada A, Chaudhuri A, Viswanathan P & Dandona P. Low-dose rosiglitazone exerts an antiinflammatory effect with an increase in adiponectin independently of free fatty acid fall and insulin sensitization in obese type 2 diabetics. Journal of Clinical Endocrinology and Metabolism 2006 91 3553-3558. (doi:10.1210/jc.2005-2609)
16. Majuri A, Santaniemi M, Rautio K, Kunnari A, Vartiainen J, Ruokonen A, Kesaniemi YA, Tapanainen JS, Ukkola O & Morin- Papunen L. Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study. European Journal of Endocrinology 2007 156 263-269. (doi:10.1530/eje.1.02331)
17. Barac A, Campia U, Matuskey LA, Lu L & Panza JA. Effects of peroxisome proliferator-activated receptor-γ activation with pioglitazone on plasma adipokines in nondiabetic patients with either hypercholesterolemia or hypertension. American Journal of Cardiology 2008 101 980-985. (doi:10.1016/j.amjcard.2007.11.058)
18. Kechagias S, Ernersson A, Dahlqvist O, Lundberg P, Lindstrom T & Nystrom FH. Fast-food-based hyper-alimentation can induce rapid and profound elevation of serum alanine aminotransferase in healthy subjects. Gut 2008 57 649-654. (doi:10.1136/gut.2007.131797)
19. Erlingsson S, Herard S, Dahlqvist Leinhard O, Lindstrom T, Lanne T, Borga M & Nystrom FH. Men develop more intraabdominal obesity and signs of the metabolic syndrome after hyperalimentation than women. Metabolism 2009 58 995-1001. (doi:10.1016/j.metabol.2009.02.028)
20. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monauni T & Muggeo M. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000 23 57-63. (doi:10.2337/diacare.23.1.57)
21. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G & Quon MJ. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. Journal of Clinical Endocrinology and Metabolism 2000 85 2402-2410. (doi:10.1210/jc.85.7.2402) (Pubitemid 32269192)
22. Claesson AL, Holm G, Ernersson A, Lindstrom T & Nystrom FH. Two weeks of overfeeding with candy, but not peanuts, increases insulin levels and body weight. Scandinavian Journal of Clinical and Laboratory Investigation 2009 69 598-605. (doi:10.1080/00365510902912754)
23. Modan-Moses D, Stein D, Pariente C, Yaroslavsky A, Ram A, Faigin M, Loewenthal R, Yissachar E, Hemi R & Kanety H. Modulation of adiponectin and leptin during refeeding of female anorexia nervosa patients. Journal of Clinical Endocrinology and Metabolism 2007 92 1843-1847. (doi:10.1210/jc.2006-1683)
24. Varady KA, Tussing L, Bhutani S & Braunschweig CL. Degree of weight loss required to improve adipokine concentrations and decrease fat cell size in severely obese women. Metabolism 2009 58 1096-1101. (doi:10.1016/j.metabol.2009. 04.010)
25. Sauma L, Stenkula KG, Kjolhede P, Stralfors P, Soderstrom M & Nystrom FH. PPAR-γ response element activity in intact primary human adipocytes: effects of fatty acids. Nutrition 2006 22 60-68. (doi:10.1016/j.nut.2005.04.011)
26. Yilmaz MI, Sonmez A, Caglar K, Gok DE, Eyileten T, Yenicesu M, Acikel C, Bingol N, Kilic S, Oguz Y & Vural A. Peroxisome proliferator-activated receptor γ (PPAR-γ) agonist increases plasma adiponectin levels in type 2 diabetic patients with proteinuria. Endocrine 2004 25 207-214. (doi:10.1385/ENDO:25:3:207)
27. Cook JR & Semple RK. Hypoadiponectinemia - cause or consequence of human "insulin resistance"? Journal of Clinical Endocrinology and Metabolism 2010 95 1544-1554. (doi:10.1210/jc.2009-2286)
28. Fogarty AW, Glancy C, Jones S, Lewis SA, McKeever TM & Britton JR. A prospective study of weight change and systemic inflammation over 9 y. American Journal of Clinical Nutrition 2008 87 30-35.
29. Visser M, Bouter LM, McQuillan GM, Wener MH & Harris TB. Elevated C-reactive protein levels in overweight and obese adults. Journal of the American Medical Association 1999 282 2131-2135. (doi:10.1001/jama.282.22.2131)
30. Tam CS, Viardot A, Clement K, Tordjman J, Tonks K, Greenfield JR, Campbell LV, Samocha-Bonet D & Heilbronn LK. Short-term overfeeding may induce peripheral insulin resistance without altering subcutaneous adipose tissue macrophages in humans. Diabetes 2010 59 2164-2170. (doi:10.2337/db10- 0162)
31. Bajnok L, Seres I, Varga Z, Jeges S, Peti A, Karanyi Z, Juhasz A, Csongradi E, Mezosi E, Nagy EV & Paragh G. Relationship of serum resistin level to traits of metabolic syndrome and serum paraoxonase 1 activity in a population with a broad range of body mass index. Experimental and Clinical Endocrinology and Diabetes 2008 116 592-599. (doi:10.1055/s-2008-1065350)
32. Rosenbaum M, Murphy EM, Heymsfield SB, Matthews DE & Leibel RL. Low dose leptin administration reverses effects of sustained weightreduction on energy expenditure and circulating concentrations of thyroid hormones. Journal of Clinical Endocrinology and Metabolism 2002 87 2391-2394. (doi:10.1210/jc.87. 5.2391)
33. Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, Wagner AJ, DePaoli AM, Reitman ML, Taylor SI, Gorden P & Garg A. Leptin-replacement therapy for lipodystrophy. New England Journal of Medicine 2002 346 570-578. (doi:10.1056/NEJMoa012437)
34. Canavan B, Salem RO, Schurgin S, Koutkia P, Lipinska I, Laposata M & Grinspoon S. Effects of physiological leptin administration on markers of inflammation, platelet activation, and platelet aggregation during caloric deprivation. Journal of Clinical Endocrinology and Metabolism 2005 90 5779-5785. (doi:10.1210/jc.2005-0780)
35. Chan JL, Bullen J, Stoyneva V, Depaoli AM, Addy C & Mantzoros CS. Recombinant methionyl human leptin administration to achieve high physiologic or pharmacologic leptin levels does not alter circulating inflammatory marker levels in humans with leptin sufficiency or excess. Journal of Clinical Endocrinology and Metabolism 2005 90 1618-1624. (doi:10.1210/jc.2004-1921)
36. Kelesidis T, Kelesidis I, Chou S & Mantzoros CS. Narrative review: the role of leptin in human physiology: emerging clinical applications. Annals of Internal Medicine 2010 152 93-100.